Gavi

Pfizer's multidose Prevenar 13 wins WHO backing

Pfizer’s blockbuster vaccine Prevenar 13 will soon get a boost in a host of international markets. The shot won WHO backing in a new, easier-to-store formulation Tuesday, enabling increased access in poor countries by reducing costs--though pricing controversy hasn’t escaped the franchise in recent days.
immunization

Gavi floats $27.5M for pilot studies of GSK's Mosquirix

Last July, WHO recommended that GlaxoSmithKline’s malaria vaccine Mosquirix be examined in pilot programs before introduction through large immunization campaigns. Now, international vaccine alliance Gavi is stepping in with conditional funding to help the upcoming real-world programs get underway.